Johnson & Johnson/Boston put case for DES (drug-eluting stents) safety at FDA stent session:
This article was originally published in Clinica
Day one of the FDA's two-day review of the safety of drug-eluting stents (DESs) closed yesterday with Boston Scientific and Johnson & Johnson telling the six-member circulatory system devices panel that their products are safe for a broad range of patients, despite findings and claims published this year of the risk of late stent restenosis (see Clinica No 1235, p 1). DESs are implanted to prevent the renarrowing of arteries, which is said to occur in some 25% of bare metal stent recipients.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.